Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy
- 1 January 1999
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (1) , 93
- https://doi.org/10.1200/jco.1999.17.1.93
Abstract
PURPOSE: Dose-dense chemotherapy is predicted to be a superior treatment plan. Therefore, we studied dose-dense doxorubicin, paclitaxel, and cyclophosphamide (A → T → C) as adjuvant therapy. METHOD...Keywords
This publication has 19 references indexed in Scilit:
- Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.Journal of Clinical Oncology, 1997
- Sequential or Alternating Doxorubicin and CMF Regimens in Breast Cancer With More Than Three Positive NodesJAMA, 1995
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- Taxol plus recombinant human granulocyte colony stimulating factor as salvage chemotherapy for metastatic breast cancerPublished by Springer Nature ,1994
- Phase I Trial of Granulocyte--Macrophage Colony-Stimulating Factor Plus High-Dose Cyclophosphamide Given Every 2 Weeks: a Cancer and Leukemia Group B StudyJNCI Journal of the National Cancer Institute, 1993
- High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.Journal of Clinical Oncology, 1993
- The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancerBritish Journal of Cancer, 1989
- Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.Journal of Clinical Oncology, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Origin of the Resistance of Leukæmic Cells to Folic Acid AntagonistsNature, 1952